Omnilink Elite™ Vascular Balloon-Expandable Stent System

Elite engineering and performance.

Strength and flexibility that provides superb results in the iliacs.

Engineering

  • Cobalt chromium multi-link technology that allows for thin struts without sacrificing strength for flexibility and vessel conformability
  • Superb accuracy with no stent shortening^
  • Thin struts to minimize vessel wall injury1
  • Dual-layer balloon for a low profile system to treat difficult-to-reach lesions

Clinical Results

  • 97.0% clinically driven freedom from TLR at 9 months
  • 91.9% patency in TASC C lesions at 2 years in iliacs2*
  • 84.8% patency in TASC D lesions at 2 years in iliacs2**

High Freedom from Clinically-Driven TLR through 3 Years

Event-Free Survival through 3 Years

 

Significant Improvement in Walking Capacity as Measured by WIQ

 

WIQ Mean Score
Stent Loop



Compliance

Stent Diameter table
Stent Close-up


Stent Sizes and Specifications

Stent Sizes and Specifications

 

Data on file at Abbott unless otherwise noted.

^-1.81% shortening for 8.0 mm x 38 mm size. Tests performed by and data on file at Abbott.
* Combined clinical results from BRAVISSIMO study where 66%/34% of TASC C lesions were treated with Absolute Pro™ Vascular Self-Expanding Stent System / Omnilink Elite™ Vascular Balloon-Expandable Stent System respectively.
**Combined clinical results from BRAVISSIMO study where 54%/46% of TASC D lesions were treated with Absolute Pro™ Vascular Self-Expanding Stent System / Omnilink Elite™ Vascular Balloon-Expandable Stent System respectively.
^^Omnilink Elite™ Vascular Balloon-Expandable Stent System Instructions For Use (IFU). Reference the IFU for additional information. 
***Max Crimped OD is 2.30 mm for the 10.0 x 59 mm stent.
 

References

  1. Pache, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. JACC 2003; 41:1283-8.
  2. Donato, G. et al. 24-Month Data from the BRAVISSIMO: A Large-Scale Prospective Registry on Iliac Stenting for TASC A & B and TASC C & D Lesions. Annals of Vascular Surgery. 2015; 29(4): 738-750.

MAT-2114533 v1.0

Important Safety Information